FineMark National Bank & Trust’s Revance Therapeutics, Inc. RVNC Stock Holding History

FineMark National Bank & Trust’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-1,700	Closed	-$35K	–	1033
2016 Q4	$35K	Sell	1,700 -6,800	-80%	-$114K	﹤0.01%	707
2016 Q3	$138K	Buy	8,500 +7,500	+750%	+$109K	0.01%	386
2016 Q2	$14K	Hold	1,000	–	–	﹤0.01%	890
2016 Q1	$17K	Hold	1,000	–	–	﹤0.01%	807
2015 Q4	$34K	Sell	1,000 -1,000	-50%	-$34.7K	﹤0.01%	711
2015 Q3	$60K	Hold	2,000	–	–	0.01%	574
2015 Q2	$64K	Hold	2,000	–	–	0.01%	588
2015 Q1	$41K	Hold	2,000	–	–	0.01%	721
2014 Q4	$34K	Hold	2,000	–	–	0.01%	777
2014 Q3	$39K	Buy	+2,000	New	+$52.1K	0.01%	703

Other funds holding RVNC

EWM

Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

FineMark National Bank & Trust's RVNC Position: Q1 2017 in Review

FineMark National Bank & Trust sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2017, closing a stake of 1,700 shares — an estimated $35K sold.

FineMark National Bank & Trust first reported a position in RVNC in Q3 2014 and held it in 10 quarters. The position peaked at $138K in Q3 2016. 78 funds tracked by Wall St. Rank hold RVNC as of Q1 2017.

FineMark National Bank & Trust reported no remaining Revance Therapeutics, Inc. position as of Q1 2017 after selling out during the quarter.
FineMark National Bank & Trust sold 1,700 Revance Therapeutics, Inc. shares in Q1 2017, an estimated $35K.
FineMark National Bank & Trust first reported a position in Revance Therapeutics, Inc. in Q3 2014 and held it in 10 quarters.
FineMark National Bank & Trust's Revance Therapeutics, Inc. position peaked at $138K in Q3 2016.
78 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2017.

Based on FineMark National Bank & Trust's 13F filing for Q1 2017, filed 12 May 2017.